Research programme: cancer therapeutics - Leuchemix

Drug Profile

Research programme: cancer therapeutics - Leuchemix

Alternative Names: LC-913 series; LC812 series; LCVJ series; LCVJ2 series

Latest Information Update: 15 Oct 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Leuchemix
  • Class
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 29 Sep 2008 Leuchemix receives approval to undertake clinical safety trials of LC 1
  • 24 Oct 2007 Preclinical development is ongoing
  • 08 Oct 2004 Preclinical trials in Solid tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top